Jingjian Liu

Dr. Jingjian Liu


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 August 2022 in Molecules
Verified
Journal Article
Open access
PDF file
QLQing Liu
Qing Liu
JLJingjian Liu
Jingjian Liu
NHNa He
Na He
MZMoli Zhang
Moli Zhang
LWLun Wu
Lun Wu
HZHua Zhang
Hua Zhang
Exosomal MicroRNA-21 (miRNA-21, miR-21) is significantly up-regulated in blood samples of patients with lung cancer. Exosomal-derived miR-21 can be used as a promising biomarker for the early diagnosis of lung cancer. This paper develops a fluorescent biosensor based on the combination of magnetic nanoparticles (MNPs), cascade strand displacement reaction (CSDR) and CRISPR/Cas12a to detect the exosomal miR-21 from lung cancer. The powerful separation performance of MNPs can eliminate the potential interference of matrix and reduce the background signal, which is very beneficial for the improvement of specificity and sensitivity. The CSDR can specifically transform one miR-21 into plenty of DNA which can specifically trigger the trans-cleavage nuclease activity of Cas12a, resulting in the cleavage of ssDNA bi-labeled with fluorescent and a quencher. Under the optimized experimental conditions, the developed fluorescence biosensor exhibited high sensitivity and specificity towards the determination of exosomal-derived miR-21 with a linear range from 10 to 1 × 105 fM and a low detection limit of about 0.89 fM. Most importantly, this method can be successfully applied to distinguish the exosomal miR-21 from the lung cancer patients and the healthy people.

1 November 2025 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
TMTingwen Ming
Tingwen Ming
YYYang Yang
Yang Yang
JZJun Zhu
Jun Zhu
JLJuncheng Lin
Juncheng Lin
WYWang Yang
Wang Yang
JLJingjian Liu
Jingjian Liu
Introduction: In recent years, plant-derived exosome-like nanoparticles (PELNs) have attracted extensive attention. Among them, Ginger-derived exosome-like nanoparticles (GELNs) represent the most extensively studied category, demonstrating a wide spectrum of pharmacological activities. However, their specific efficacy against lung cancer remains largely unexplored and warrants further investigation. The appropriate isolation of GELNs is fundamental to all related research, yet a systematic comparison of different extraction methods is currently lacking. This study aimed to evaluate the differences among GELNs extracted by various methods and to investigate their anti-lung cancer pharmacological activities. Methods: The study employed four common isolation methods—ultracentrifugation (UC), sucrose gradient UC (sgUC), membrane filtration, and polyethylene glycol-based precipitation (PEG-based precipitation) - to isolate GELNs. The GELNs were characterized by transmission electron microscopy (TEM), nanoparticle tracking analysis (NTA), and zeta potential measurements. Stability was evaluated under various conditions, including saline, serum, and different storage temperatures. The compositional profiles of GELNs extracted by four methods were explored using non-targeted metabolomics. A549 cells and PC-9 cells were used to assess the cellular uptake and anti-lung cancer efficacy of the four GELNs types. Network pharmacology, molecular docking, and molecular dynamics simulations were integrated to elucidate the potential mechanisms underlying their anti-lung cancer effects. Results: The four methods successfully isolated GELNs with distinct profiles: UC achieved the highest protein yield (1.630 ± 0.022 g/kg), membrane filtration yielded the highest particle concentration (46.9 ± 6.71× 108 particles/mL) but the lowest protein yield (0.059 ± 0.002 g/kg). Stability studies indicated that the highest stability of GELNs was observed for those isolated by UC and sgUC in both 0.9% and 10% NaCl. Furthermore, GELNs prepared by UC and membrane filtration showed excellent stability in serum. It was also demonstrated that − 80°C provided the optimal storage condition for GELNs. Non-targeted metabolomics revealed the presence of 649 shared metabolites among the GELNs extracted by the four methods, along with method-specific unique metabolites. GELNs extracted by all four methods were internalized by both A549 and PC-9 cells. Among them, UC-isolated GELNs demonstrated the most potent anti-proliferative activity against the lung cancer cells. Through network pharmacology, 21 key targets of UC-isolated GELNs against lung cancer were identified. Molecular docking and molecular dynamics simulations further verified that 10-Gingerol, Hexahydrocurcumin, and [6]-Dehydrogingerdione from GELNs could stably bind to key targets, including Glycogen Synthase Kinase-3β (GSK3B), Progesterone Receptor (PGR), and SRC Proto-Oncogene, Non-Receptor Tyrosine Kinase (SRC). Conclusion: This study demonstrates that although all four methods can isolate GELNs, UC is recommended for fundamental research due to its high protein yield, excellent stability, and potent in vitro anti-lung cancer activity. Furthermore, the anti-lung cancer activity of GELNs may be attributed to the regulation of GSK3B, PGR, and SRC by 10-Gingerol, Hexahydrocurcumin, and [6]-Dehydrogingerdione.

6 June 2025 in Frontiers in Chemistry
Verified
Journal Article
Open access
PDF file
TMTingwen Ming
Tingwen Ming
YYYang Yang
Yang Yang
BSBing Shang
Bing Shang
ZLZhihao Li
Zhihao Li
FRFangling Ren
Fangling Ren
JLJingjian Liu
Jingjian Liu
Background: Polygonatum sibiricum has a long history of medicinal and edible usages, and has attracted widespread attention from researchers due to its rich pharmacological activities. Research has found that plant-derived exosome-like nanoparticles (PELNs) have enormous potential in the field of biomedicine, such as serving as natural nanomedicines to treat diseases or as carriers for drug delivery. However, there are no studies on P. sibiricum-derived exosome-like nanoparticles (PSELNs) against cancer.Methods: This work used ultracentrifugation to extract the PSELNs and characterized them using transmission electron microscopy (TEM), nanoparticle tracking analysis (NTA), and dynamic light scattering (DLS). Proteomics and metabolomics were used to analyze the components of the PSELNs, and the Herb database was used to screen for active metabolites. The OMIM and TTD databases were used to analyze active metabolites, and we further speculated that they may have anti-breast cancer (BC) activity. Network pharmacology was used to analyze the possible mechanisms of the PSELNs against BC, mainly including protein-protein interaction (PPI) network analysis for potential targets, gene ontology (GO) for analyzing biological processes, and Kyoto Encyclopedia of Genes and Genomes (KEGG) for analyzing related signaling pathways. After that, the related data of BC was retrieved from the GEO database, and the clinical expression and survival prognosis of the key genes screened by network pharmacology were analyzed by bioinformatics. Molecular docking and Molecular dynamics (MD) simulation were used to verify the binding of active metabolites in the PSELNs with their targets. Finally, the CCK-8 method was used to validate the inhibitory effect of the PSELNs on BC.Results: Firstly, TEM, NTA, and DLS confirmed that the PSELNs were successfully isolated. Then, Proteomics identified 18 protein components from the PSELNs, including ATP synthase subunit alpha, protein Ycf2, and Mannose/silica acid binding lectin. Metabolomics identified 357 metabolic components from the PSELNs and further screened 23 active metabolites by oral bioavailability (OB), including Sedanolide, Baicalein, and 6-Gingerol, etc. By analyzing 23 active metabolites, it was speculated that the PSELNs may have pharmacological activity against BC. After that, network pharmacology was used to screen 23 key targets of the PSELNs against BC. KEGG and GO enrichment analysis showed that the MAPK signaling pathway, PI3k-Akt signaling pathway, and AMPK signaling pathway were involved in the anti-BC effect of the PSELNs. Through bioinformatics analysis of 23 key targets in BC clinical samples, it was found that, except for ESR1, which was significantly upregulated, CAV1, FGF2, and PPARG were all significantly downregulated. The expression levels of 4 targets were positively correlated with survival status. These 4 targets were validated by molecular docking and MD simulation with active metabolites in the PSELNs, and it was found that the binding of sedanolide and ESR1, Baicalein and PPARG, and 6-Gingerol and ESR1 can remain stable. Finally, The inhibitory effect of the PSELNs on BC cells (MDA-MB-231) was validated by the CCK-8 method.Conclusion: This was the first time that the PSELNs have been studied against cancer. It was verified that they have anti-BC activity, and the mechanism may be related to targets such as ESR1 and PPARG, regulated by active metabolites in the PSELNs. This work laid a foundation and reference for more follow-up related research studies.

7 October 2025 in BMC Plant Biology
Verified
Journal Article
Open access
PDF file
WYWang Yang
Wang Yang
ZLZhihao Li
Zhihao Li
JLJuncheng Lin
Juncheng Lin
CKChanghu Ke
Changhu Ke
HLHuimin Liu
Huimin Liu
PLPeng Li
Peng Li
Paris polyphylla Sm. is a precious medicinal plant rich in various active ingredients. In addition to the well-known saponins, the flavonoids it contains have unique pharmacological potential in antioxidant, neuroprotective, and metabolic regulation. However, the flavonoids in Paris polyphylla Sm. have not been fully researched and developed yet. In this work, we conducted a comprehensive metabolomics and transcriptomics analysis to reveal the metabolic differences and biosynthetic mechanisms of flavonoids in the leaves, stems, and roots of Paris polyphylla Sm. Non-targeted metabolomics analysis detected a total of 332 metabolites in Paris polyphylla Sm., among which flavonoids accounted for 19.49%. The diversity and abundance of flavonoids in leaves are the highest, followed by stems and roots. By comparing the metabolites of the roots, stems, and leaves in Paris polyphylla Sm., it was found that there were 45 differential metabolites (DMs) between the leaves and roots, of which flavonoids accounted for 35%. There are 38 DMs between leaves and stems, of which flavonoids account for 45.45%. And there are 52 DMs in stems and roots, among which flavonoids account for 25.53%. A total of 62,766 genes were detected by transcriptomics, and pairwise comparison showed that there were tens of thousands of differentially expressed genes (DEGs) between each group. Afterwards, we selected 39 flavonoids and related metabolites (e.g., kaempferol-3-O-glucoside, quercetin 3-β-D-glucoside, rutin) for targeted metabolomics validation and performed RT-qPCR validation on 29 key flavonoid synthesis genes (e.g., C4H, CHS, FLS, F3’H) to verify the reliability of non-targeted metabolomics and transcriptomics. This work indicated that leaves are the main site for the biosynthesis of flavonoids in Paris polyphylla Sm. Among them, kaempferol-3-O-glucoside, quercetin 3-β-D-glucoside, rutin, and other flavonoids are present in higher contents in leaves (P < 0.05). Further research on its biosynthetic mechanism indicates that naringenin chalcone is converted to naringenin by chalcone isomerase (CHI). Among them, CHI may be the rate-limiting enzyme in the biosynthesis of flavonoids in Paris polyphylla Sm. The expression of FLS is higher in leaves (P < 0.05) and tends to promote the synthesis of flavonols. This work promotes the utilization of non-medicinal parts of Paris polyphylla Sm. and enhances the sustainable development of this precious traditional Chinese medicine resource.

1 January 2025 in Journal of Analytical Methods in Chemistry
Verified
Journal Article
Open access
YYYang Yang
Yang Yang
LRLiu Renyan
Liu Renyan
XLXin Lingyi
Xin Lingyi
FBFeng Baodong
Feng Baodong
ZYZhang Yu
Zhang Yu
QCQinhua Chen
Qinhua Chen
Objective: Aconitine alkaloids, as the principal bioactive constituents of Fuzi, pose a significant challenge to its clinical application due to their toxicity. This study aimed to establish a rapid, efficient, and stable method for quantifying monoester‐type and diester‐type alkaloids in raw Fuzi using zeolitic imidazolate framework‐8 (ZIF‐8). The method was subsequently applied to pharmacokinetic studies in rats, offering valuable insights into the safe clinical use of Fuzi. Methods: Synthetic ZIF‐8 was employed as the microextraction adsorbent, with optimization of extraction parameters such as ZIF‐8 content, shaker speed, extraction time, and sodium ion concentration to maximize enrichment efficiency. A dispersive solid‐phase extraction–liquid chromatography–tandem mass spectrometry (d‐SPE–LC–MS/MS) method, based on ZIF‐8, was developed and validated for method performance. The pharmacokinetics of five aconitine alkaloids in Fuzi were investigated, ensuring efficient extraction and analysis. Results: Under the optimized conditions, the d‐SPE method demonstrated robust enrichment of aconitine alkaloids. A strong linear relationship was established for aconitine, hypaconitine, mesaconitine, lappaconitine, and benzoylaconitine within the concentration range of 0.3125–1000 ng/mL, with correlation coefficients exceeding 0.99. The LC–MS/MS assay achieved a detection limit as low as 0.104 ng/mL. Additionally, the pharmacokinetic analysis revealed rapid absorption of the five alkaloids, with benzoylaconitine exhibiting a T max of 0.25 h. Conclusion: This study introduces a novel d‐SPE–LC–MS/MS method based on ZIF‐8 for the analysis of aconitine alkaloids in plasma, facilitating pharmacokinetic studies of Fuzi. These findings substantially contribute to a deeper understanding of the in vivo pharmacokinetics of aconitine alkaloids.